PNH is primarily an Alternative Pathway-mediated disease, with no involvement of the Classical or Lectin pathways in its pathology.

MBL (mannose-binding lectin), a pattern recognition molecule circulating in complex with MASPs (MBL-associated serine proteases), activates the lectin complement pathway and facilitates thrombin ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic ...

C3G and IC-MPGN cause protein deposits that reduce kidney function. Treatment helps lower or prevent kidney damage.

In the classical pathway it is activated by antibodies, so it is an antigen driven pathway. In the lectin pathway, carbohydrate epitopes on microbes are recognized.

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...

The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-bl ...

The point I'm making here is that this and other C5 inhibitors, with downstream lectin/active pathway inhibition, leads to FDA boxed label warnings of risk for serious bacterial infections.

Lectin Pathway and Its Initiators in Brain Ischemia Early studies reported that MBL, the first recognition molecule activating LP to be identified 11 and one of the most widely studied, is involved in ...

Study reveals ketamine's potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.